Home Featured Page 143

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer...

PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...

1...142143144...303 Page 143 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces...

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural...

Braxia Scientific Announces Board Appointment

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian...

HAVN Life Provides Corporate Update

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of...

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health...

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer...

PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The...

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY